AKBA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Akebia Therapeutics dosed the first patient in a Phase 2 basket trial of ebrikafusp for rare complement-mediated kidney diseasesSep 14, 2026
- Akebia Therapeutics initiated a Phase 2 basket trial of ebribafusp in rare kidney diseasesAug 3, 2026
- Akebia Therapeutics dosed the first participants in Phase 1 trial of AKB-9090Apr 13, 2026
- U.S. patient data for Vadadustat from global Phase 3 program published in Journal of the American Society of NephrologyJun 4, 2025